Statin use after radical prostatectomy reduces biochemical recurrence in men with prostate cancer

Prostate

Volumn 75, Issue 2, 2015, Pages 211-217

  Song, Cheryn ^a   Park, Sejun ^b   Park, Jinsung ^c   Shim, Myungsun ^a   Kim, Aram ^a   Jeong, In Gab ^a   Hong, Jun Hyuk ^a   Kim, Choung Soo ^a   Ahn, Hanjong ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Ulsan University College of Medicine   (South Korea)

^c Eulji University   (South Korea)

Author keywords

Biochemical recurrence; HMG CoA reductase inhibitor; Prognosis; Prostate cancer; Radical prostatectomy; Statin

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; KALLIKREIN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BIOCHEMICAL RECURRENCE FREE SURVIVAL; CANCER PATIENT; CANCER STAGING; CONTROLLED STUDY; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; KOREAN (PEOPLE); MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RISK REDUCTION; TREATMENT DURATION; TREATMENT OUTCOME; BLOOD; FOLLOW UP; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDY; TRENDS;

AGED; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KALLIKREINS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84923279772     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22907     Document Type: Article

References (24)

1. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001-1009.
2. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-1357.
3. Serruys PW, de Feyter P, Macaya C, Kokott N, Puel J, Vrolix M, Branzi A, Bertolami MC, Jackson G, Strauss B, Meier B. Lescol Intervention Prevention Study I. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: A randomized controlled trial. JAMA 2002;287: 3215-3222.
4. Altucci L, Addeo R, Cicatiello L, Dauvois S, Parker MG, Truss M, Beato M, Sica V, Bresciani F, Weisz A. 17Beta-estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)- arrested human breast cancer cells. Oncogene 1996;12:2315-2324.
5. Wong WW, Dimitroulakos J, Minden MD, Penn LZ. HMG-CoA reductase inhibitors and the malignant cell: The statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 2002;16: 508-519.
6. Kaushal V, Kohli M, Mehta P, Mehta JL. Potential anticancer effects of statins: Fact or fiction? Endothelium 2003;10:49-58.
7. Roy M, Kung HJ, Ghosh PM. Statins and prostate cancer: Role of cholesterol inhibition vs. prevention of small GTP-binding proteins. Am J Cancer Res 2011;1:542-561.
8. Papadopoulos G, Delakas D, Nakopoulou L, Kassimatis T. Statins and prostate cancer: Molecular and clinical aspects. Eur J Cancer 2011;47:819-830.
9. Flick ED, Habel LA, Chan KA, Van Den Eeden SK, Quinn VP, Haque R, Orav EJ, Seeger JD, Sadler MC, Quesenberry CP Jr, Sternfeld B, Jacobsen SJ, Whitmer RA, Caan BJ. Statin use and risk of prostate cancer in the California Men's Health Study cohort. Cancer Epidemiol Biomarkers Prev 2007;16:2218-2225.
10. Murtola TJ, Tammela TL, Lahtela J, Auvinen A. Cholesterollowering drugs and prostate cancer risk: A population-based case-control study. Cancer Epidemiol Biomarkers Prev 2007;16: 2226-2232.
11. Platz EA, Leitzmann MF, Visvanathan K, Rimm EB, Stampfer MJ, Willett WC, Giovannucci E. Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 2006;98:1819-1825.
12. Mass AY, Agalliu I, Laze J, Lepor H. Preoperative statin therapy is not associated with biochemical recurrence after radical prostatectomy: Our experience and meta-analysis. J Urol 2012;188:786-791.
13. Scosyrev E, Tobis S, Donsky H, Wu G, Joseph J, Rashid H, Messing E. Statin use and the risk of biochemical recurrence of prostate cancer after definitive local therapy: A meta-analysis of eight cohort studies. BJU Int 2013;111:E71-77.
14. Laucks SP Jr, McLachlan MS. Aging and simple cysts of the kidney. Br J Radiol 1981;54:12-14.
15. Fowke JH, Motley SS, Barocas DA, Cookson MS, Concepcion R, Byerly S, Smith JA Jr. The associations between statin use and prostate cancer screening, prostate size, high-grade prostatic intraepithelial neoplasia (PIN), and prostate cancer. Cancer Causes Control 2011;22:417-426.
16. Bonovas S, Filioussi K, Sitaras NM. Statin use and the risk of prostate cancer: A metaanalysis of 6 randomized clinical trials and 13 observational studies. Int J Cancer 2008;123:899-904.
17. Hager MH, Solomon KR, Freeman MR. The role of cholesterol in prostate cancer. Curr Opin Clin Nutr Metab Care 2006;9:379-385.
18. Krane LS, Kaul SA, Stricker HJ, Peabody JO, Menon M, Agarwal PK. Men presenting for radical prostatectomy on preoperative statin therapy have reduced serum prostate specific antigen. J Urol 2010;183:118-124.
19. Mondul AM, Han M, Humphreys EB, Meinhold CL, Walsh PC, Platz EA. Association of statin use with pathological tumor characteristics and prostate cancer recurrence after surgery. J Urol 2011;185:1268-1273.
20. Hamilton RJ, Banez LL, Aronson WJ, Terris MK, Platz EA, Kane CJ, Presti JC Jr, Amling CL, Freedland SJ. Statin medication use and the risk of biochemical recurrence after radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. Cancer 2010;116:3389-3398.
21. Kollmeier MA, Katz MS, Mak K, Yamada Y, Feder DJ, Zhang Z, Jia X, Shi W, Zelefsky MJ. Improved biochemical outcomes with statin use in patients with high-risk localized prostate cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys 2011;79:713-718.
22. Hamilton RJ, Goldberg KC, Platz EA, Freedland SJ. The influence of statin medications on prostate-specific antigen levels. J Natl Cancer Inst 2008;100:1511-1518.
23. Gutt R, Tonlaar N, Kunnavakkam R, Karrison T, Weichselbaum RR, Liauw SL. Statin use and risk of prostate cancer recurrence in men treated with radiation therapy. J Clin Oncol 2010;28:2653-2659.
24. Murtola TJ, Tammela TL, Maattanen L, Huhtala H, Platz EA, Ala-Opas M, Stenman UH, Auvinen A. Prostate cancer and PSA among statin users in the Finnish prostate cancer screening trial. Int J Cancer 2010;127:1650-1659.